See full prescribing information for PRADAXA Capsules. PRADAXA (dabigatran etexilate) capsules, for oral use. Initial U.S. Approval: 2024. WARNING: (A)
See full prescribing information for PRADAXA Capsules. PRADAXA (dabigatran etexilate) capsules, for oral use. Initial U.S. Approval: 2024
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRADAXA Oral Pellets safely and effectively. See full prescribing information for PRADAXA Oral Pellets. PRADAXA (dabigatran etexilate) oral pellets . Initial U.S. Approval: 2024 . WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA
HIGHLIGHTS OF PRESCRIBING INFORMATION. These highlights do not include all the information needed to use. PRADAXA safely and effectively. See full prescribing
See full prescribing information for PRADAXA. PRADAXA (dabigatran etexilate Amiodarone: When dabigatran etexilate was coadministered with a single
PRADAXA safely and effectively. See full prescribing information for. PRADAXA. PRADAXA (dabigatran etexilate mesylate) capsules for oral use. Initial U.S.
PRADAXA safely and effectively. See full prescribing information for PRADAXA. PRADAXA (dabigatran etexilate) capsules, for oral use Initial U.S. Approval: 2024 . WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL HEMATOMA. See full prescribing information for complete boxed warning
HIGHLIGHTS OF PRESCRIBING INFORMATION. These highlights do not include all the information needed to use PRADAXA Capsules safely and effectively. See full prescribing information for
Pradaxa [Prescribing Information] (2024) Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield.
Comments